Sanofi and MassBio Partner to Identify and Support Groundbreaking Innovations in Cell and Gene Therapy & Immunology and Inflammation

Sep 14, 2021

Sanofi 2021’s Pharma Days® on October 18 & 19 will catalyze precision partnering

September 14, 2021 (CAMBRIDGE, MA) – The Massachusetts Biotechnology Council (MassBio®) and Sanofi today issued a call for the world’s most innovative academics, entrepreneurs, and early-stage biotechs focused on breakthroughs in cell and gene therapy and immunology and inflammation. Through Sanofi’s 2021 Pharma Days® on October 18 and 19, the global healthcare leader will work to strengthen collaboration across the life sciences innovation ecosystem by showcasing its partnering capabilities, platforms, and expertise while connecting directly with potential collaborators.

“We actively seek transformational ideas at Sanofi and our goal is to be key contributors in bringing them to patients worldwide,” explains Alban de La Sablière, Head of Sanofi Partnering. “We have strong pipeline momentum, and the best way to sustain this is to find complementary matches in terms of products, mechanism of action, talent, infrastructure, and technologies. Our investments add novel modalities to our toolbox and strengthen our pipeline approach in diseases where patients need urgent solutions. We look forward to discovering new research and technologies through our partnership with MassBio.” 

On October 18th, from 8 – 9 AM ET and from 3 – 4 PM ET, leaders from Sanofi will provide an overview of their R&D efforts, corporate development strategy, business areas, and novel and fully integrated approaches to partnering. Biotech companies, entrepreneurs, academics, research institutions, accelerators, and incubators can register here to participate in these open information sessions.

Innovators across all stages of development with a strong understanding of their technology’s path to product are encouraged to apply for a one-on-one meeting with Sanofi representatives to discuss potential collaboration opportunities. Sanofi’s therapeutic areas of interest are:

  • Cell and gene therapies & gene editing technologies
  • Immunology and inflammation

To apply for a partnering meeting on October 18 or 19, please visit The deadline to apply is September 17.

“As the last 18 months have demonstrated, partnerships between emerging startups and academic institutions and established biopharma companies have the potential to transform patient lives and deliver unprecedented scientific breakthroughs,” said Kendalle Burlin O’Connell, President and COO, MassBio. “At MassBio, we strive to create the necessary pathways for these organizations to connect and catalyze lasting change. Sanofi has been a staple of the Massachusetts life sciences cluster for years, and I look forward to seeing how they will leverage the partnerships born from our upcoming Pharma Days to address the world’s most complicated unmet medical needs.”

MassBio’s Pharma Days® provide unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. Since 2010, MassBio has facilitated more than 1,000 connections between emerging entrepreneurs and established biopharmaceutical companies through Pharma Days® and other partnering initiatives.

See all MassBio News